MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial

MAIA Biotechnology, Inc. ( (MAIA) ) has issued an update.

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company specializing in targeted immuno-oncology therapies, is developing ateganosine (THIO), a first-in-class telomere-targeting agent for non-small cell lung cancer (NSCLC). The company focuses on treatments for patients whose telomerase-positive cancers have progressed beyond standard checkpoint inhibitor regimens.

On April 8, 2026, MAIA announced that net proceeds from a $33 million common stock offering completed in March 2026 are expected to fully fund its ongoing pivotal Phase 3 THIO-104 trial of ateganosine in third-line NSCLC. The Fast Track–designated therapy is being tested in up to 300 patients against standard chemotherapy, with management highlighting strong investor participation and statistical assessments suggesting a high probability of technical success if Phase 3 results align with prior Phase 2 data.

The THIO-104 global, multicenter, open-label study evaluates ateganosine followed by a checkpoint inhibitor in patients resistant to checkpoint inhibitors and chemotherapy, using overall survival as the primary endpoint and safety as a key objective. Successful completion of this fully funded Phase 3 program could strengthen MAIA’s position in the NSCLC market by offering a novel telomere-targeting and immune-activating option for heavily pretreated patients.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical and immuno-oncology company focused on developing targeted therapies for cancer. Its lead program is ateganosine (THIO), a potential first-in-class telomere-targeting agent in clinical development for non-small cell lung cancer (NSCLC) patients with telomerase-positive tumors.

The company aims to commercialize novel mechanisms of action intended to improve and extend the lives of people with cancer, with a current focus on second- or later-line treatment settings. MAIA is listed on the NYSE American under the ticker MAIA and concentrates on telomere- and immune-based approaches to address resistant disease.

Average Trading Volume: 1,090,859

Technical Sentiment Signal: Sell

Current Market Cap: $72.81M

See more insights into MAIA stock on TipRanks’ Stock Analysis page.